New conditions now available in TreatGxPlus

New conditions now available in TreatGxPlus

The team at Genxys is excited to announce that Post-Myocardial Infarction (Heart Attack) and Smoking Cessation are now covered in TreatGxPlus (pharmacogenetic test and decision support system).

Post-Myocardial Infarction (Heart Attack)

A myocardial infarction (MI) is also known as a heart attack. This occurs when the heart muscle does not receive enough blood or oxygen because one or more of the arteries leading to the heart are blocked.

TreatGxPlus covers medications used to prevent another heart attack or cardiovascular event. Most people will take five medications after experiencing a heart attack including: ACE inhibitor or angiotensin receptor blocker, aspirin, antiplatelet, beta-blocker, and statin.

There are four pharmacogenetic markers over the five classes of medications to help tailor your prescription therapy right from the start.


Smoking Cessation

The decision to quit smoking is a big step to improving your health. It is never too late to quit and the benefits include lower risk of developing cancer, heart and lung disease, as well as improved quality of life.

TreatGxPlus covers nicotine replacement therapy and prescription therapies used to quit smoking


There is one pharmacogenetic marker associated with reduced response to one of the medication options covered in TreatGxPlus.


Stay tuned for more exciting news and updates about new conditions and medications.

About TreatGxPlus

TreatGxPlus is a smart online tool that helps you and your doctor identify safe and effective medications that are right for you, right from the start. TreatGxPlus combines your pharmacogenetic and medical profile with the best evidence.

In Canada, TreatGxPlus is brought to you in partnership with LifeLabs

No Comments

Sorry, the comment form is closed at this time.